Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-000397-18
    Sponsor's Protocol Code Number:MedOPP341
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-08-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-000397-18
    A.3Full title of the trial
    A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI
    Studio multicentrico, in aperto, a braccio singolo di Fase II per valutare l'efficacia e la sicurezza della combinazione di Pembrolizumab e Lenvatinib in pazienti con carcinoma del timo pretrattati. PECATI
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase II study of the combination of Pembrolizumab and Lenvatinib, in pre-treated thymic CArcinoma paTIents (PECATI).
    Studio di Fase II sulla combinazione di Pembrolizumab e Lenvatinib, in pazienti con Carcinoma timico pretrattato (PECATI).
    A.3.2Name or abbreviated title of the trial where available
    PECATI
    PECATI
    A.4.1Sponsor's protocol code numberMedOPP341
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMEDICA SCIENTIA INNOVATION RESEARCH S.L.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck Sharp & Dohme Corp. (MSD)
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMedica Scientia Innovation Research S.L (MEDSIR)
    B.5.2Functional name of contact pointMª del Mar Zafra
    B.5.3 Address:
    B.5.3.1Street AddressTorre Glòries, Avda.Diagonal 211, planta 27
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08018
    B.5.3.4CountrySpain
    B.5.4Telephone number0034932214135
    B.5.5Fax number0034932214135
    B.5.6E-mailmariadelmar.zafra@medsir.org
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePEMBROLIZUMAB
    D.3.2Product code [MK-3475]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPembrolizumab
    D.3.9.1CAS number 1374853-91-4
    D.3.9.2Current sponsor codePembrolizumab
    D.3.9.3Other descriptive nameMK-3475
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name KEYTRUDA (pembrolizumab, MK-3475
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Sharp & Dohme B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameKEYTRUDA
    D.3.2Product code [KEYTRUDA]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPembrolizumab
    D.3.9.1CAS number 1374853-91-4
    D.3.9.2Current sponsor codeMK-3475
    D.3.9.3Other descriptive nameMK-3475
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLenvatinib
    D.3.2Product code [E7080]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLenvatinib Mesilate
    D.3.9.1CAS number 857890-39-2
    D.3.9.2Current sponsor codeLenvatinib Mesilate
    D.3.9.3Other descriptive nameLenvatinib Mesilate
    D.3.9.4EV Substance CodeSUB72971
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLenvatinib
    D.3.2Product code [E7080]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLenvatinib Mesilate
    D.3.9.1CAS number 857890-39-2
    D.3.9.2Current sponsor codeLenvatinib Mesilate
    D.3.9.3Other descriptive nameLenvatinib Mesilate
    D.3.9.4EV Substance CodeSUB72971
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic Thymic Carcinoma & B3-thymoma
    Carcinoma timico metastatico e timoma B3
    E.1.1.1Medical condition in easily understood language
    Metastatic Thymic Carcinoma & B3-thymoma
    Carcinoma timico metastatico e timoma B3
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10043670
    E.1.2Term Thymoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10055108
    E.1.2Term Thymic cancer metastatic
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of pembrolizumab and lenvatinib in pre-treated relapsed/recurrent B3-thymoma and Thymic carcinoma (TC) patients in terms of progression free survival (PFS) rate at 5 months.
    Valutare l'efficacia di pembrolizumab e lenvatinib in pazienti con timoma B3 recidivato/ricorrente e carcinoma timico (TC) pretrattati, in termini di tasso di sopravvivenza libera da progressione (PFS) a 5 mesi.
    E.2.2Secondary objectives of the trial
    • To assess the efficacy of pembrolizumab and lenvatinib in pre-treated advanced B3-thymoma and TC patients in terms of PFS, response rate (RR), disease control rate (DCR) Duration of response (DoR), tumor shrinkage and overall survival (OS).
    • To assess the safety and toxicity profile of the combination according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v.5.0).
    • Valutare l'efficacia di pembrolizumab e lenvatinib in pazienti con timoma B3 avanzato e TC pretrattati in termini di PFS, tasso di risposta (RR), tasso di controllo della malattia (DCR) durata della risposta (DoR), riduzione della massa del tumore e sopravvivenza complessiva (OS).
    • Valutare il profilo di sicurezza e tossicità della combinazione secondo i Criteri Comuni di Terminologia per gli Eventi Avversi Versione 5.0 (CTCAE v. 5.0).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Relapsed / Recurrent histologically confirmed B3-Thymoma or TC patients not amenable to curative-intent radical surgery and/or radiotherapy, regardless of PD-L1 expression.
    2. Patients progress after at least one previous line of platinum-based chemotherapy for advanced disease:
    a. Patients treated with neo-adjuvant or adjuvant platinum-based chemotherapy combined with radical surgery or as part of radical chemo-radiotherapy are eligible if chemotherapy was completed within 6
    months before enrolment.
    3. Negative result for Myasthenia Gravis (MG) by acetylcholine receptor antibodies test. Presence of acetylcholine receptor antibodies will be considered a positive result for MG, regardless of the value.
    4. Male/female who are at least 18 years of age on the day of signing informed consent.
    5. ECOG performance status 0-1
    6. Life expectancy = 3 months
    7. Radiological progression documented per RECIST 1.1 during or after completion of previous line therapy, per investigator's criteria.
    8. Presence of measurable disease according to RECIST 1.1 criteria. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
    a. Disease status must be documented by full chest and upper abdomen (including adrenal glands) CT and/or MRI within 28 days prior study enrolment. If clinically indicated, brain imaging must be performed;
    9. Provides historical (obtained archived FFPE) or fresh tumor biopsy specimen for biomarker studies, if feasible. Archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated is acceptable. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archival tissue. Note: If submitting unstained cut slides, newly cut slides should be submitted to the testing laboratory within 14
    days from the date slides are cut.
    10. A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:
    a) Not a woman of childbearing potential (WOCBP) as defined in
    Appendix 3
    OR
    b) A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 6 months after the last dose of study treatment.
    11. Adequate bone marrow and organ function according to Table 1 (section 3.1.1).
    12. Written informed consent prior to beginning specific protocol procedures.
    1. Pazienti con timoma B3 o TC recidivo/ricorrente confermato istologicamente, non suscettibili di chirurgia radicale a scopo curativo e/o radioterapia, indipendentemente dall'espressione di PD-L1.
    2. Pazienti in progressione dopo almeno una precedente linea di chemioterapia a base di platino per patologia avanzata:
    a. I pazienti trattati con chemioterapia neo-adiuvante o adiuvante a base di platino in combinazione con chirurgia radicale o come parte della chemio-radioterapia radicale sono ammissibili se la chemioterapia è stata completata entro i 6 mesi precedenti all’arruolamento.
    3. Risultato negativo per la miastenia grave (MG) al test degli anticorpi del recettore dell'acetilcolina. La presenza di anticorpi del recettore dell'acetilcolina sarà considerata un risultato positivo per MG, indipendentemente dai valori.
    4. Uomo/donna di almeno 18 anni compiuti al giorno della firma del consenso informato.
    5. Status prestazioni ECOG 0-1
    6. Aspettativa di vita = 3 mesi
    7. Progressione radiologica documentata per RECIST 1.1 durante o dopo il completamento della precedente terapia di linea, secondo i criteri dello sperimentatore.
    8. Presenza di malattia misurabile secondo i criteri RECIST 1.1. Le lesioni situate in un'area precedentemente irradiata sono considerate misurabili se è dimostrata una progressione in tali lesioni.
    a. Lo stato della malattia deve essere documentato da TC e/o RM complete del torace e dell'addome superiore (comprese le ghiandole surrenali) entro i 28 giorni precedenti l'iscrizione allo studio. Sarà richiesto imaging cerebrale qualora clinicamente indicato;
    9. Ove possibile, presentazione di campione bioptico storico (FFPE acquisito archiviato) o fresco del tumore per l’analisi dei biomarcatori. Sono accettabili campioni di tessuto tumorale d'archivio o un nucleo appena ottenuto o una biopsia escissionale di una lesione tumorale non precedentemente irradiata. Sono preferibili blocchi di tessuto fissati alla formalina e incorporati in paraffina (FFPE) rispetto ai vetrini. Sono preferibili biopsie appena ottenute rispetto a tessuti di archivio. Nota: Se si presentano vetrini tagliati non colorati, una volta tagliati i vetrini devono essere presentati in laboratorio entro 14 giorni dalla data di taglio.
    10. Per poter essere ammesse, le donne devono non essere incinte (si veda Appendice 3), non allattare al seno e soddisfare almeno una delle seguenti condizioni:
    a) Non essere in età fertile (WOCBP) come definita in Appendice 3
    Oppure
    b) Se in età fertile, accettare di seguire le linee guida contraccettive riportate in Appendice 3 durante il periodo di trattamento e per almeno 6 mesi dopo l'ultima dose del trattamento in studio.
    11. Adeguata funzionalità del midollo osseo e degli organi secondo la tabella 1 (paragrafo 3.1.1).
    12. Consenso informato scritto prima di avviare specifiche procedure di protocollo.
    E.4Principal exclusion criteria
    1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PDL2 agent or with an agent directed to another stimulatory or coinhibitoryT-cell receptor (e.g., CTLA-4, OX 40, CD137).
    2. Has received prior therapy with sunitinib.
    3. Any evidence of active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are clinically stable (i.e. without evidence of progression by imaging for at least four weeks prior to enrolment and any neurologic symptoms have returned to baseline), and have not received steroids (for a total equivalent dose of more than 10 mg of prednisone per day) for at least 7 days prior to enrolment.
    4. Presence of acetylcholine receptor antibodies regardless of the value.
    5. Uncontrolled blood pressure (Systolic BP>140 mmHg or diastolic BP >90 mmHg) in spite of an optimized regimen of antihypertensive medication.
    6. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.
    7. Intratumor cavitation, direct invasion of main mediastinal blood vessels by the tumor or exist previous bleeding.
    8. Fraction ejection < 50%
    9. Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in the last 15 days prior to enrolment:
    a. Daily prednisone at doses up to 10 mg or equivalent doses of any other corticosteroid is allowed for example as replacement therapy;
    10. History of interstitial lung disease (ILD) OR pneumonitis (other than COPD exacerbation) that has required oral or IV steroids;
    11. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (i.e.,
    thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed;
    12. History of any other hematologic or primary solid tumor malignancy, unless in remission for at least 5 years and without specific treatment (as example, not allowed hormonal therapy to replace for
    breast cancer or hormonal therapy substitution in prostate cancer). pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, nonmelanomatous skin cancer or carcinoma in situ of the cervix are allowed;
    13. Previous allogenic tissue/solid organ transplantation
    14. Active infection requiring systemic therapy.
    15. Has received prior radiotherapy within 2 weeks of start of study treatment.
    16. Has an intestinal disease not allowing swallowing pills.
    1. Precedente terapia con un agente anti-PD-1, anti-PD-L1 o anti-PD-L2 o con un agente diretto ad un altro recettore stimolatore o co-inibitore delle cellule T (ad esempio, CTLA-4, OX-40, CD137).
    2. Precedente terapia con sunitinib.
    3. Evidenza di metastasi attive del sistema nervoso centrale (SNC) e/o meningite carcinomatosa. I pazienti precedentemente trattati con metastasi cerebrali sono ammessi a partecipare a condizione che siano clinicamente stabili (cioè senza evidenza di progressione da imaging per almeno quattro settimane prima dell'arruolamento e se gli eventuali sintomi neurologici sono tornati al basale), e non abbiano ricevuto steroidi (per una dose totale equivalente a più di 10 mg di prednisone al giorno) per almeno 7 giorni prima dell'iscrizione.
    4. Presenza di anticorpi del recettore dell'acetilcolina indipendentemente dai valori.
    5. Pressione sanguigna incontrollata (BP sistolica>140 mmHg o BP diastolica >90 mmHg) nonostante un regime ottimizzato di farmaci antipertensivi.
    6. Compromissione cardiovascolare significativa: anamnesi di insufficienza cardiaca congestizia superiore alla classe II della New York Heart Association (NYHA), angina instabile, infarto miocardico o ictus nei 6 mesi precedenti alla prima dose del farmaco in studio o aritmia cardiaca che richieda un trattamento medico allo screening.
    7. Cavitazione intratumorale, invasione diretta dei principali vasi sanguigni mediastinici da parte del tumore o sanguinamento precedente.
    8. Espulsione frazione <50%.
    9. Uso cronico di agenti immunosoppressori e/o corticosteroidi sistemici o qualsiasi uso negli ultimi 15 giorni prima dell'arruolamento:
    a. Dosi giornaliere fino a 10 mg di prednisone o dosi equivalenti di qualsiasi altro corticosteroide sono consentite, ad esempio come terapia sostitutiva.
    10. Anamnesi di patologia polmonare interstiziale (ILD) o polmonite (diversa da esacerbazione della BPCO) che ha richiesto steroidi per via orale o endovenosa.
    11. Malattia autoimmune attiva che abbia richiesto un trattamento sistemico negli ultimi 2 anni (ossia con uso di agenti modificanti la malattia corticosteroidi o farmaci immunosoppressori). La terapia sostitutiva (ad es. tiroxina, insulina o terapia sostitutiva con steroidi fisiologici per insufficienza surrenalica o ipofisaria, ecc.) non è considerata una forma di trattamento sistemico ed è consentita;
    12. Anamnesi di qualsiasi altro tumore maligno solido ematologico o primario, tranne se in remissione per almeno 5 anni e senza trattamento specifico (ad esempio, non è consentita la terapia ormonale sostitutiva per il cancro al seno o la terapia ormonale sostitutiva per il cancro alla prostata). Sono ammissibili cancro prostatico pT1-2 con Gleason score < 6, cancro della vescica superficiale, cancro della pelle non melanomatoso o carcinoma in situ della cervice.
    13. Precedente trapianto di tessuti allogenici/organi solidi.
    14. Infezione attiva che richieda una terapia sistemica
    15. Precedente radioterapia nelle 2 settimane precedenti l'inizio del trattamento in studio.
    16. Patologia intestinale che non consente di deglutire le pillole
    E.5 End points
    E.5.1Primary end point(s)
    • Progression free survival (PFS) rate at 5 months, defined as the percentage of patients with B3-Thymoma and TC without disease progression at 5 months after starting the treatment combination.
    • Tasso di sopravvivenza libera da progressione (PFS) a 5 mesi, definito come percentuale di pazienti con timoma B3 e TC senza progressione della malattia a 5 mesi dall'inizio della combinazione farmacologica.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Time from randomization to disease progression
    Dalla randomizzazione alla progressione della malattia
    E.5.2Secondary end point(s)
    • Response rate (RR) with the treatment combination
    • Maximum tumor shrinkage with the treatment combination
    • Disease control rate (DCR) with the treatment combination
    • Duration of response (DoR) with the treatment combination
    • Overall survival (OS)
    • Safety and toxicity profile of the combination according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v.5.0).
    • Tasso di risposta (RR) con la combinazione farmacologica
    • Massima riduzione della massa del tumore con la combinazione farmacologica
    • Tasso di controllo della malattia (DCR) con la combinazione farmacologica
    • Durata della risposta (DoR) con la combinazione farmacologica
    • Sopravvivenza complessiva (OS)
    • Profilo di sicurezza e tossicità della combinazione secondo il National Cancer Institute Common Terminology Criteria for Adverse Events Versione 5.0 (CTCAE v. 5. 0).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Time from randomization to disease progression
    Dalla randomizzazione alla progressione della malattia
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of study date, or clinical cut-off, is defined as the Last Patient Last Visit (LPLV) at the end of the follow-up period. This will be the last data collection point, which can be a clinic visit, a sample analysis or a follow-up phone contact. Unless premature termination of the study, end of study date will occur on the last safety follow-up visit after the last dose of study treatment is administered to the last patient in the
    study.
    End of study date, or clinical cut-off, is defined as the Last Patient Last Visit (LPLV) at the end of the follow-up period. This will be the last data collection point, which can be a clinic visit, a sample analysis or a follow-up phone contact. Unless premature termination of the study, end of study date will occur on the last safety follow-up visit after the last dose of study treatment is administered to the last patient in the
    study.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months32
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months32
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 13
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 30
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 43
    F.4.2.2In the whole clinical trial 43
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care
    Standard di pratica clinica
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-07-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-06-17
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 23:15:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA